Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Lutz

Showing results (71-80 of 119) with videos related to

Pageof 12
Sort By:
AIDS (London, England)|July 1, 2010
The cytotoxic lymphocyte antigen 4 polymorphisms affect response to hepatitis C virus-specific therapy in HIV(+) patients with acute and chronic hepatitis C virus co-infectionHans Dieter Nischalke, Martin Vogel, Stefan Mauss, et al.
HIV Medicine|May 28, 2024
Still trouble with bleeding: Risk factors for HCV transmission in men who have sex with men and behavioural trajectories from 2019 to 2021Axel Jeremias Schmidt, Peter Weatherburn, Haoyi Wang, et al.
Antiviral Therapy|February 28, 2017
Telaprevir-containing triple therapy in acute HCV coinfection: The CHAT StudyChristoph Boesecke, Gurmit K Jagjit Singh, Stefan H-A Scholten, et al.
Antiviral Therapy|May 11, 2011
Nevirapine versus atazanavir/ritonavir, each combined with tenofovir disoproxil fumarate/emtricitabine, in antiretroviral-naive HIV-1 patients: the ARTEN TrialVicente Soriano, Keikawus Arastéh, Horacio Migrone, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 29, 2019
Reinfection With the Hepatitis C Virus in Men Who Have Sex With Men After Successful Treatment With Direct-acting Antivirals in Germany: Current Incidence Rates, Compared With Rates During the Interferon EraPatrick Ingiliz, Malte H Wehmeyer, Christoph Boesecke, et al.
Plos One|August 1, 2015
Benefit of Treatment Individualization in Patients with Chronic Hepatitis C Receiving Peginterferon Alfa-2a and Ribavirin in a Large Noninterventional Cohort StudyWolf Peter Hofmann, Stefan Mauss, Thomas Lutz, et al.
The Journal of Antimicrobial Chemotherapy|March 6, 2010
Daily dosing of tacrolimus in patients treated with HIV-1 therapy containing a ritonavir-boosted protease inhibitor or raltegravirMarkus Bickel, Evrim Anadol, Martin Vogel, et al.
Plos One|May 13, 2022
Establishing a framework towards monitoring HCV microelimination among men who have sex with men living with HIV in Germany: A modeling analysisLara K Marquez, Patrick Ingiliz, Christoph Boesecke, et al.
International Journal of Molecular Sciences|June 16, 2016
Persistence of HCV in Acutely-Infected Patients Depletes C24-Ceramide and Upregulates Sphingosine and Sphinganine Serum LevelsGeorgios Grammatikos, Julia Dietz, Nerea Ferreiros, et al.
BMC Gastroenterology|March 29, 2012
Assessment of liver fibrosis and associated risk factors in HIV-infected individuals using transient elastography and serum biomarkersJohannes Vermehren, Annika Vermehren, Axel Mueller, et al.
Pageof 12

Showing results (71-80 of 119) with videos related to

Sort By:
Pageof 12
AIDS (London, England)|July 1, 2010
The cytotoxic lymphocyte antigen 4 polymorphisms affect response to hepatitis C virus-specific therapy in HIV(+) patients with acute and chronic hepatitis C virus co-infectionHans Dieter Nischalke, Martin Vogel, Stefan Mauss, et al.
HIV Medicine|May 28, 2024
Still trouble with bleeding: Risk factors for HCV transmission in men who have sex with men and behavioural trajectories from 2019 to 2021Axel Jeremias Schmidt, Peter Weatherburn, Haoyi Wang, et al.
Antiviral Therapy|February 28, 2017
Telaprevir-containing triple therapy in acute HCV coinfection: The CHAT StudyChristoph Boesecke, Gurmit K Jagjit Singh, Stefan H-A Scholten, et al.
Antiviral Therapy|May 11, 2011
Nevirapine versus atazanavir/ritonavir, each combined with tenofovir disoproxil fumarate/emtricitabine, in antiretroviral-naive HIV-1 patients: the ARTEN TrialVicente Soriano, Keikawus Arastéh, Horacio Migrone, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 29, 2019
Reinfection With the Hepatitis C Virus in Men Who Have Sex With Men After Successful Treatment With Direct-acting Antivirals in Germany: Current Incidence Rates, Compared With Rates During the Interferon EraPatrick Ingiliz, Malte H Wehmeyer, Christoph Boesecke, et al.
Plos One|August 1, 2015
Benefit of Treatment Individualization in Patients with Chronic Hepatitis C Receiving Peginterferon Alfa-2a and Ribavirin in a Large Noninterventional Cohort StudyWolf Peter Hofmann, Stefan Mauss, Thomas Lutz, et al.
The Journal of Antimicrobial Chemotherapy|March 6, 2010
Daily dosing of tacrolimus in patients treated with HIV-1 therapy containing a ritonavir-boosted protease inhibitor or raltegravirMarkus Bickel, Evrim Anadol, Martin Vogel, et al.
Plos One|May 13, 2022
Establishing a framework towards monitoring HCV microelimination among men who have sex with men living with HIV in Germany: A modeling analysisLara K Marquez, Patrick Ingiliz, Christoph Boesecke, et al.
International Journal of Molecular Sciences|June 16, 2016
Persistence of HCV in Acutely-Infected Patients Depletes C24-Ceramide and Upregulates Sphingosine and Sphinganine Serum LevelsGeorgios Grammatikos, Julia Dietz, Nerea Ferreiros, et al.
BMC Gastroenterology|March 29, 2012
Assessment of liver fibrosis and associated risk factors in HIV-infected individuals using transient elastography and serum biomarkersJohannes Vermehren, Annika Vermehren, Axel Mueller, et al.
Pageof 12